Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07220096

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

The goal of this research study is to learn about:

The effect of enrolling in the YOLC program on patient satisfaction with care provided,

The needs of patients younger than 50 with lung cancer and their family, and

The impact of participating in peer support networks on these patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

Eric Singhi, MD

CONTACT

[email protected]

713-745-2263

Eric Singhi, MD

PRINCIPAL_INVESTIGATOR

About this study

Primary Objectives:

  • To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
  • To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
  • To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.

Secondary Objectives:

  • To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided.
  • To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway.
  • To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.
  • Overall survival, defined by time from diagnosis to death from any cause
  • Clinical trial enrollment, defined by participation in any therapeutic clinical trial related to lung cancer treatment after diagnosis
  • Completion of multi-disciplinary consultations, defined by patients completing consultations with at least one other specialist other than a thoracic medical oncologist or thoracic surgeon from time of initial consultation for the YOLC Program
  • Quality of life, as defined by FACT-LUNG
  • Financial toxicity, as defined by patient-reported financial burden, including out-of-pocket costs, insurance coverage issues, and impact of overall financial well-being (measured using validated financial toxicity scale such as COST-FACIT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than 18 years and under 50 years
  • Histologic confirmation of NSCLC
  • Able to complete an English-language survey independently or with the assistance of a native-language interpreter
  • Pregnant women- may be enrolled due to age range of subjects. (Low risk)

Exclusion criteria

  • Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study.
  • The following special patient population will be excluded from study group:
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners
  • Cognitively-impaired adults

Treatment and study plan

Survey

Other

Participants will complete an intake survey and repeat surveys at the following time points:

  • Baseline
  • 3 months
  • 6 months
  • 9 months
  • 12 months
  • 18 months
  • 24 months
  • 36 months
  • 48 months
  • 60 months

Primary outcomes

  1. Participant satisfaction with care

    Time frame: Through study completion; an average of 5 year

    Assessed via validated survey instruments (e.g., FACT-L, COST-FACIT).

    • Focus on detecting even small changes in survey responses over time (baseline, 3, 6, 9, 12 months, etc.).

Study contacts

Contact information is provided by the study sponsor or research team.

Eric Singhi, MD

CONTACT

[email protected]

713-745-2263

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start
2025
Primary completion
2029
Study completion
2031
First posted
Oct 23, 2025
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.